REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat lymphoma: weekly drug combo shows promise
Disease control OngoingThis study tests whether giving a targeted drug (brentuximab vedotin) weekly, with or without another drug (nivolumab), can shrink tumors in people with CD30+ lymphoma that came back or didn't respond to standard treatment. About 28 adults with relapsed or refractory Hodgkin or n…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
New combo therapy shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—selinexor and choline salicylate—in 22 adults with certain blood cancers (lymphoma, multiple myeloma, or histiocytic/dendritic cell tumors) that have come back or not responded to prior treatment. The main goal is to fi…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 04:33 UTC
-
Promising combo for tough hodgkin lymphoma cases shows strong response
Disease control OngoingThis study tested a combination of the immunotherapy drug nivolumab and chemotherapy (ICE) in 78 people with Hodgkin lymphoma that returned or didn't respond to initial treatment. The goal was to see if this approach could shrink tumors enough to allow a stem cell transplant. The…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New combo therapy shows promise for tough hodgkin lymphoma cases
Disease control OngoingThis study tests two immunotherapy drugs, ipilimumab and nivolumab, alone or together, in people with classic Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to shrink or control the cancer. About 13 adults are taking part. The approach aims to…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
New drug combo after transplant shows promise against tough hodgkin lymphoma
Disease control OngoingThis study tests whether two immunotherapy drugs, nivolumab and brentuximab vedotin, can help prevent Hodgkin lymphoma from coming back after a stem cell transplant. It includes 62 people with high-risk lymphoma that had returned or didn't respond to earlier treatment. The goal i…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New combo therapy aims to outsmart tough hodgkin lymphoma
Disease control OngoingThis small pilot study tests whether giving a PD-1 inhibitor after CAR-T cell therapy can improve outcomes for people with Hodgkin lymphoma that has come back or not responded to treatment. Ten adults who have already tried at least three prior therapies will receive standard ant…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:37 UTC